Bioheart Reports Year End 2008 Results; Reviews 2008 and 1Q09 Progress and 2009 Business Objectives

Print
| Source: Bioheart, Inc.

SUNRISE, Fla., May 7, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Pink Sheets:BHRT) reports financial results for the year ended December 31, 2008, provides a review of its progress in 2008 and 1Q 2009 and outlines 2009 annual business objectives. Bioheart's Form 10-K was filed on April 15, 2009 and Bioheart's Form 10-K/A was filed on April 30, 2009.

Highlights 1Q 2009



 * Completed call center set up to support at-home heart failure
   monitoring.
 * Began shipments of Bioheart 3370 Heart Failure Monitoring Systems
   in U.S. market.
 * Initiated streamlining of MyoCell(r) MARVEL clinical protocol
   design to reduce costs and implement additional safety monitoring
   including 24-hour call center beat-to-beat ECG monitoring following
   myoblast implantation.
 * Presented MyoCell(r) clinical data at the 5th Annual Cell Therapy
   for Cardiovascular Diseases Meeting in New York and the American
   College of Cardiology Meeting in Orlando, Florida.
 * Sold $104,350 worth of Bioheart MyoCath(r) catheters to researchers
   and reached $109,000 in revenues for the quarter.
 * Renegotiated BlueCrest loan at favorable terms. Reduced monthly
   payments from $180,000 to $31,520 through June 2009.

Highlights for 2008 include the following:



 * Increased from 5 clinical sites for MyoCell(r) in the USA to 35 in
   Phase II/III clinical trial for advanced heart failure.
 * Presented results from Phase II SEISMIC study of MyoCell
   demonstrating that 83% to 94% of treated patients improved in CHF
   class and/or 6-minute walk while only 6% to 17% worsened; whereas,
   in the control group treated only with drugs, 69% worsened.
 * Obtained CE Mark commercial approval for Bioheart TGI-1200 stem
   cell processing device and disposables.
 * Launched sales of Bioheart 3370 Heart Failure Monitoring Systems
   with U.S. FDA 510(k) authorization and CMS reimbursement.
 * Acquired rights to Bioheart-Monebo Cardiobelt(r) with FDA 510(k)
   authorization.
 * Acquired certain rights to Bioheart A&C Bio Science T-PLS(r) true
   pulsatile life support system with CE Mark commercial approval.
 * Expanded MyoCell(r) production capacity from 30 cases per month to
   over 1,000 with new commercial scale facility in Asia in
   partnership with Bioheart Manufacturing Asia, Inc. (BHM, Inc.)
 * Bioheart received two new pioneering patents for utilizing
   electrical stimulation to enhance muscle stem cell transplantation
   for treating heart failure including patent claims for converting
   stem cells to heart cells.
 * Achieved total revenues in 2008 of $154,051.

Bioheart reduced its monthly operating expenses in the third and fourth quarters of 2008 from a September 2008 peak of $1.5 million down to $444,078 in January mostly due to a decrease in general and administrative and research and development expenses, offset in part by a planned increase in sales and marketing expenses. The Company anticipates continued significant reduction in operating expenses in 2009 as Bioheart further shifts its resources toward managing sales and marketing activities, assumed mostly by its distribution partners, and away from research and development. The Company expects to keep reduced cash operating losses to approximately $500,000 per month in the near term.

Net loss for 2008 was $14.2 million or $0.97 per share on a basic and diluted basis, as compared to $18.07 million, or $1.37 per share on a basic and diluted basis for 2007. The reduction to net loss is attributable in part to decreased operating expenses but was offset by increased sales and marketing expenses, coinciding with market launches for the Bioheart 3370 Heart Failure Monitoring System and the Bioheart TGI-1200 Stem and Endothelial Progenitor Cell Processing System, as well as pre-clinical studies for MyoCell SDF-1, now moving into clinical trial, and acquisition of the Bioheart-Monebo Cardiobelt(r).

Bioheart, Inc. ended the year reaching the milestone of $82,532,746 in additional paid-in capital. Over the course of its history Bioheart has utilized over $30 million in grant funding bringing the total invested in research programs and company development since founding to $122 million. Cash and cash equivalents were $50,091 on December 31, 2008 compared to $5.5 million as of December 31, 2007. The Company will require additional capital in the near term for its operations to bridge to the point where profits from revenues can totally support expenses.

For further information on the company's year end 2008 financial results, please refer to Bioheart's Form 10-K filed with the SEC on April 15, 2009 (SEC file number 001-33718) and 10-K/A filed with the SEC on April 30, 2009 (SEC file number 001-33718).

2009 Business Objectives

Bioheart's business objectives for 2009 and beyond include the following:



 * Reach Bioheart 3370 Heart Failure Monitoring Systems sales of an
   annual run rate of $22 million.  FDA 510(k), European CE Mark and
   Reimbursement already in place.
 * Complete interim analysis of MARVEL Study patients.
 * Expand global distribution network in Europe and Asia-Pacific and
   related sales pact.
 * Move MyoCell(r) SDF-1 second-generation composition for advanced
   heart failure into Phase II/III pivotal clinical trial.
 * Launch U.S. 510(k) authorized Bioheart-Monebo Cardiobelt(r) in U.S.
   market.
 * Keep operating loss for year to under $5.4 million.
 * Publish in peer reviewed journals Phase II SEISMIC and MYOHEART U.S.
   Dose Escalation Study Results.
 * Gain reimbursement approval for MyoCell in Europe for treating
   sickest heart failure patients.
 * Launch sales of CE Mark approved Bioheart A&C Bio Science T-PLS(r)
   Twin-Pulsatile Life Support System system in Europe.
 * Finish development with corporate partner of implantable heart
   failure sensor that communicates wirelessly with the Bioheart 3370
   Heart Failure Monitoring System.
 * Finish development of implantable heart pump on percutaneous
   catheter with corporate partner in Korea, A&C Bio Science, Inc.
 * Sell off rights to non-core intellectual property and product
   developments to increase cash available for core heart failure
   focused developments:  AortaCell, MyoStim, MyoValve, BioPace,
   EndoCell, and MyoCath.
 * Seek joint venture partner to commercially develop the A&C Bio
   Science LVAD/SVAD, a significantly lower-cost left ventricle assist
   device co-developed by Bioheart.
 * Continue to add devices to product lineup that feed information
   into the Bioheart 3370 24-hour monitoring system.

About Bioheart, Inc.

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(r), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(r) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.

MyoCell, MyoCell SDF-1 and MyoCath are trademarks of Bioheart, Inc.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

Bioheart, Inc.
Howard J. Leonhardt, Chief Executive Officer
(954) 835-1500

RedChip Companies, Inc.
Investor Relations:
Dave Gentry
(800) 733-2447, Ext. 104